Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenlingcao is a traditional Chinese herbal medicine formulation marketed as "Shenlingcao oral liquid." It is used primarily as a complementary therapy to improve quality of life and reduce fatigue in patients with conditions such as long COVID-associated fatigue and non-small cell lung cancer (NSCLC) undergoing adjuvant chemotherapy. The formulation contains American Ginseng (Panacis Quinquefolii Radix), Lucid Ganoderma (Ganoderma), Rose (Rosae Rugosae Flos), and fermented Cordyceps powder. Clinical trials have shown that it can improve physical, role, and emotional function scores in NSCLC patients receiving chemotherapy, as well as alleviate symptoms like fatigue, nausea/vomiting, appetite loss, and performance status over a 6-month follow-up period. Its mechanism of action is not fully elucidated but may involve immunomodulatory effects[1][2][3][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shenlingcao.